logo
  

RedHill Biopharma Releases Positive Data For Its Opaganib In Covid-19 Treatment

RedHill Biopharma Ltd. (RDHL) Monday said Opaganib, the company's antiviral drug candidate for the treatment of Covid-19, showed strong inhibition against South African and Brazilian variants in preclinical study.

Partnered with the University of Louisville Center for Predictive Medicine, opaganib was studied in a 3D tissue model of human bronchial epithelial cells to evaluate the in vitro efficacy of opaganib in inhibiting the Beta, South African and Gamma, Brazilian SARS-CoV-2 variants.

Opaganib exerts its antiviral effect by selectively inhibiting sphingosine kinase-2 (SK2), a key enzyme produced in human cells that can be recruited by the virus to support its replication.

RedHill Biopharma said opaganib's Phase 2/3 study in hospitalized patients with Covid-19 is fully enrolled and is expected to be completed in the coming weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million...
Follow RTT